Patients with CKD present various defects in hemostasis and coagulation including the elevation platelet aggregation and von Willebrand factor activity, and the plasma concentrations of D-dimer, fibrinogen, and plasminogen activator inhibitor that prevents the activation of the fibrinolytic system [33, 34]. This evidence concerns the gene SERPINB2 and chronic kidney disease.